For patients diagnosed with gastric or gastroesophageal junction (G/GEJ) adenocarcinoma:

CLDN18.2:
Identify and interpret with confidence

Claudin 18.2 (CLDN18.2) identifies a previously undefined population of patients with G/GEJ adenocarcinoma. CLDN18.2 is detected via IHC testing.1

Claudin 18.2 (CLDN18.2) identifies a previously undefined population of patients with G/GEJ adenocarcinoma. CLDN18.2 is detected via IHC testing.1

What is CLDN18.2?

How to interpret stains

Learn to evaluate samples across the spectrum of CLDN18.2 expression.

Learn how

Peer perspectives

Matteo Fassan, MD, PhD

University of Padua.
Padua, Italy

Takeshi Kuwata, MD, PhD

National Cancer Center Hospital East.
Tokyo, Japan

Kristina A. Matkowskyj, MD, PhD

University of
Wisconsin School of Medicine and Public Health; William S. Middleton VA Medical Center.
Madison, WI, USA

Christoph Röcken,
MD

University Hospital
Schleswig Holstein (UKSH).
Kiel, Germany

Josef H.
Rüschoff, MD

Discovery Life
Sciences Biomarker Services.
Kassel, Germany

Meet our panel of leading experts, who will provide evaluation and guidance on the CLDN18.2 biomarker.

The experts above have been contracted as paid advisors through Astellas Pharma Inc. and have received compensation for their time.

See expert profiles

CLDN18.2, claudin 18 isoform 2; G/GEJ, gastric/gastroesophageal junction; IHC, immunohistochemistry.

CLDN18.2,claudin 18 isoform 2; G/GEJ, gastric/
gastroesophageal junction; IHC, immunohistochemistry.

Stay up to date on CLDN18.2

By signing up below, you will receive updates about testing for CLDN18.2 expression in G/GEJ adenocarcinoma. You may also be contacted by an Astellas representative. 

Please provide a valid Email.
You must agree before submitting.
You must agree before submitting.

Successful registration

Reference: 1. Kage H, Flodby P, Zhou B, Borok Z. Dichotomous roles of claudins as tumor promoters or suppressors: lessons from knockout mice. Cell Mol Life Sci 2019;76(23):4663-72.